RRAD

Across TCGA pan-cancer cohorts, RRAD RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated RRAD data layer compared with 3 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher RRAD RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RRAD expression acts as an unfavorable survival marker, although some lineages such as CESC and ACC show a favorable association.

MESO, CESC, and ACC are the cancer types where RRAD RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	All	0.271	0.502	<.001	107	view →
CESC	DFS	Tertile	II,III,IV	0.904	0.639	<.001	102	view →
ACC	DFS	Tertile	All	0.843	0.342	<.001	47	view →
LUSC	OS	Quartile	All	0.574	0.781	<.001	46	view →
UVM	OS	Median	III,IV	0.289	1.000	.005	43	view →
SKCM	OS	Tertile	III,IV	0.555	0.339	.005	33	view →
THCA	DFS	Tertile	II,III,IV	0.872	0.988	.011	20	view →
LIHC	OS	Quartile	III,IV	0.358	0.764	.005	16	view →
KIRC	OS	Tertile	All	0.833	0.907	.011	15	view →
CHOL	DFS	Tertile	All	0.476	0.142	.013	15	view →
ESCA	OS	Tertile	II,III,IV	0.596	0.797	.014	13	view →
LGG	OS	Quartile	All	0.379	0.551	.020	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

RRAD–MESO (OS)

Open the MESO breakdown →